Any current/future capex/capital investment/strategic investment?

Unit 3 Greenfield Project: A 200-acre Phase I construction project at Kakinada is progressing well. Production Start: Production activities at Unit 3 are expected to commence towards the end of Q1 FY 2024-25. Capital Work in Progress: INR 496 crores as of September 30, 2023, with INR 263 crores related to the Kakinada project. Previous Spend: INR 76 crores spent till the previous year on Kakinada project. Advances: INR 67 crores in advances for the Kakinada project as of September 2023. Impact on Expenses: Operational expenses expected to rise as Unit 3 setup completes and production scales up

Future growth expectations in sales/revenue/volumes?

Divi's Laboratories anticipates strong growth opportunities, especially in contrast media, sartans, and soon-to-expire patent products. Custom synthesis business shows robust growth; 2 large projects are now at full production, expected to contribute more in coming quarters. Nutraceutical segment growing at 10-15%, with dominant position in complex carotenoids like astaxanthin. Stable generic API demand with good volume trends, despite current pricing pressures. Pricing pressure and inventory cycles in generics expected to stabilize within 2 years. New product filings (DMFs) expected to fuel g

Future growth expectations in earnings/operating earnings/profits/EPS?

Divi’s Laboratories anticipates numerous growth opportunities, particularly in contrast media, sartans, and products with soon-to-expire patents (Page 3). Custom synthesis projects have gone into full-scale production; results from these will be visible in coming quarters, signaling growth in this segment (Pages 6, 7). Contrast media (iodine-based) products are growing well; gadolinium-based product supplies expected to start picking up in FY 2025 (Page 8). Despite pricing pressures in generics, volume growth and new DMFs filed are expected to contribute to growth beyond FY 2025 (Pages 4, 8).

Current/ Expected Orderbook/ Pending Orders?

Divi's Laboratories has two major custom synthesis projects with big pharma, both fully on production and contributing to strong growth. The company has received billion-dollar scale orders from CDMOs for peptide building blocks and related reagents, signaling a substantial opportunity starting light in 2025. The contrast media segment is progressing, with iodine-based products growing well and gadolinium-based products in the final development and approval stages, expected to pick up in fiscal 2025. The Kakinada greenfield project is under construction and set to start production in Q1 FY 202

Divi's Lab.Q2 FY24Pharmaceuticals & Biotechnology

Divi's Lab. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹9,664P/E: 86.1Market Cap: ₹2.6L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Divi's Laboratories anticipates strong growth opportunities, especially in contrast media, sartans, and soon-to-expire patent products.
Custom synthesis business shows robust growth; 2 large projects are now at full production, expected to contribute more in coming quarters.
Nutraceutical segment growing at 10-15%, with dominant position in complex carotenoids like astaxanthin.
Stable generic API demand with good volume trends, despite current pricing pressures.
Pricing pressure and inventory cycles in generics expected to stabilize within 2 years.
New product filings (DMFs) expected to fuel growth beyond FY 2025.
Expansion of Unit 3 underway; production beginning Q1 FY '25 expected to support volume growth.
Peptide building blocks business progressing well, aiming to become a major supplier soon.
Overall, double-digit like-for-like growth YoY anticipated excluding COVID-related sales.

Margin guidance

Category 3

Divi’s Laboratories anticipates numerous growth opportunities, particularly in contrast media, sartans, and products with soon-to-expire patents (Page 3).
Custom synthesis projects have gone into full-scale production; results from these will be visible in coming quarters, signaling growth in this segment (Pages 6, 7).
Contrast media (iodine-based) products are growing well; gadolinium-based product supplies expected to start picking up in FY 2025 (Page 8).
Despite pricing pressures in generics, volume growth and new DMFs filed are expected to contribute to growth beyond FY 2025 (Pages 4, 8).
Inventory destocking and pricing pressure cycles typically last up to 2 years, with an expected subsequent recovery (Page 14).
Unit 3 production commencement expected in Q1 FY 2025 will increase operational capacity and support growth (Page 5).
Overall, double-digit like-to-like growth was reported excluding COVID portfolio, indicating sustained strong future earnings potential (Page 5).

See what Divi's Lab. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript from the Divi's Laboratories Limited Q2 FY24 earnings call does not mention any current or planned fundraising through debt or equity. Key points include: - No discussion or disclosure of new debt or equity issuance. - Capital expenditure is ongoing, particularly for Unit 3 greenfield project, funded internally (INR 263 crores spent on Kakinada project till date). - Cash on hand is substantial (INR 3,604 crores as of September 30, 2023). - Operational expenses for new Unit 3 expected to increase, but no mention of external funding plans. - Management focuses on organic growth and utilization of internal resources. Therefore, as per the latest call transcript, no current or future fundraising through debt or equity is indicated.

Order book

Divi's Laboratories has two major custom synthesis projects with big pharma, both fully on production and contributing to strong growth.
The company has received billion-dollar scale orders from CDMOs for peptide building blocks and related reagents, signaling a substantial opportunity starting light in 2025.
The contrast media segment is progressing, with iodine-based products growing well and gadolinium-based products in the final development and approval stages, expected to pick up in fiscal 2025.
The Kakinada greenfield project is under construction and set to start production in Q1 FY 2025, enabling capacity expansion and freeing up existing facilities for new projects.
Molnupiravir sales remain significant but specific current orderbook figures for this or other products are not disclosed due to confidentiality agreements.
Overall, the orderbook reflects a diversified spread across multiple therapeutic segments and long-term growth engines with robust pipeline visibility.

See what Divi's Lab. management said on order book — free account, 30 seconds.

Capex plans

Yes

Unit 3 Greenfield Project: A 200-acre Phase I construction project at Kakinada is progressing well.
Production Start: Production activities at Unit 3 are expected to commence towards the end of Q1 FY 2024-25.
Capital Work in Progress: INR 496 crores as of September 30, 2023, with INR 263 crores related to the Kakinada project.
Previous Spend: INR 76 crores spent till the previous year on Kakinada project.
Advances: INR 67 crores in advances for the Kakinada project as of September 2023.
Impact on Expenses: Operational expenses expected to rise as Unit 3 setup completes and production scales up.
Objective: Unit 3 will free up facilities in Units 1 and 2 for new Custom Synthesis and Generic Products opportunities.

Track Divi's Lab. — get its next earnings analysis in your feed

How does Divi's Lab. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisDivi's Lab.

Rev 3Mar 3

See where Divi's Lab. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Divi's Lab. rank in Pharmaceuticals & Biotechnology?

Compare Divi's Lab. against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Torrent Pharmaceuticals Ltd vs Laurus Labs Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Divi's Lab. Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Divi's Lab. rank in Pharmaceuticals & Biotechnology?

Continue your research

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season